RESHAPE LIFESCIENCES INC (RSLS) Fundamental Analysis & Valuation

NASDAQ:RSLS • US76090R3093

Current stock price

3.92 USD
+0.72 (+22.5%)
At close:
3.22 USD
-0.7 (-17.86%)
After Hours:

This RSLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RSLS Profitability Analysis

1.1 Basic Checks

  • RSLS had negative earnings in the past year.
  • In the past year RSLS has reported a negative cash flow from operations.
  • In the past 5 years RSLS always reported negative net income.
  • RSLS had a negative operating cash flow in each of the past 5 years.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • RSLS has a worse Return On Assets (-53.42%) than 66.84% of its industry peers.
  • Looking at the Return On Equity, with a value of -281.54%, RSLS is doing worse than 77.01% of the companies in the same industry.
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 63.74%, RSLS is in the better half of the industry, outperforming 65.24% of the companies in the same industry.
  • RSLS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RSLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RSLS Health Analysis

2.1 Basic Checks

  • RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RSLS has been increased compared to 1 year ago.
  • Compared to 5 years ago, RSLS has more shares outstanding
  • RSLS has a worse debt/assets ratio than last year.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5K 10K 15K 20K 25K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • RSLS has an Altman-Z score of -130.89. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
  • RSLS has a worse Altman-Z score (-130.89) than 96.26% of its industry peers.
  • RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -130.89
ROIC/WACCN/A
WACC8.88%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.53 indicates that RSLS should not have too much problems paying its short term obligations.
  • RSLS's Current ratio of 1.53 is on the low side compared to the rest of the industry. RSLS is outperformed by 73.80% of its industry peers.
  • A Quick Ratio of 0.91 indicates that RSLS may have some problems paying its short term obligations.
  • RSLS's Quick ratio of 0.91 is on the low side compared to the rest of the industry. RSLS is outperformed by 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 0.91
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. RSLS Growth Analysis

3.1 Past

  • RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.64%, which is quite impressive.
  • RSLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.93%.
  • The Revenue has been growing by 19.54% on average over the past years. This is quite good.
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

More info and screens

Find the best growth stocksShow best growing peers

0

4. RSLS Valuation Analysis

4.1 Price/Earnings Ratio

  • RSLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RSLS Dividend Analysis

5.1 Amount

  • No dividends for RSLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RSLS Fundamentals: All Metrics, Ratios and Statistics

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (8/14/2025, 8:00:01 PM)

After market: 3.22 -0.7 (-17.86%)

3.92

+0.72 (+22.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12
Earnings (Next)11-12
Inst Owners0.73%
Inst Owner Change-100%
Ins Owners0.06%
Ins Owner Change0%
Market Cap81.26M
Revenue(TTM)7.17M
Net Income(TTM)-3.46M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.33
P/FCF N/A
P/OCF N/A
P/B 66.07
P/tB 66.07
EV/EBITDA N/A
EPS(TTM)-212.11
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.35
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 0.91
Altman-Z -130.89
F-Score3
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.15%
OCF growth 3YN/A
OCF growth 5YN/A

RESHAPE LIFESCIENCES INC / RSLS Fundamental Analysis FAQ

What is the fundamental rating for RSLS stock?

ChartMill assigns a fundamental rating of 2 / 10 to RSLS.


What is the valuation status for RSLS stock?

ChartMill assigns a valuation rating of 0 / 10 to RESHAPE LIFESCIENCES INC (RSLS). This can be considered as Overvalued.


How profitable is RESHAPE LIFESCIENCES INC (RSLS) stock?

RESHAPE LIFESCIENCES INC (RSLS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RSLS stock?

The Earnings per Share (EPS) of RESHAPE LIFESCIENCES INC (RSLS) is expected to grow by 20% in the next year.